Oncolytic viruses

perspectives on clinical development

James Burke, Jorge Nieva, Mitesh J Borad, Caroline J. Breitbach

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.

Original languageEnglish (US)
Article number486
Pages (from-to)55-60
Number of pages6
JournalCurrent Opinion in Virology
Volume13
DOIs
StatePublished - Jun 15 2015

Fingerprint

Oncolytic Viruses
Oncolytic Virotherapy
Neoplasms
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Virology

Cite this

Oncolytic viruses : perspectives on clinical development. / Burke, James; Nieva, Jorge; Borad, Mitesh J; Breitbach, Caroline J.

In: Current Opinion in Virology, Vol. 13, 486, 15.06.2015, p. 55-60.

Research output: Contribution to journalArticle

Burke, James ; Nieva, Jorge ; Borad, Mitesh J ; Breitbach, Caroline J. / Oncolytic viruses : perspectives on clinical development. In: Current Opinion in Virology. 2015 ; Vol. 13. pp. 55-60.
@article{862677cb9c6744f0a474594afce8c429,
title = "Oncolytic viruses: perspectives on clinical development",
abstract = "Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.",
author = "James Burke and Jorge Nieva and Borad, {Mitesh J} and Breitbach, {Caroline J.}",
year = "2015",
month = "6",
day = "15",
doi = "10.1016/j.coviro.2015.03.020",
language = "English (US)",
volume = "13",
pages = "55--60",
journal = "Current Opinion in Virology",
issn = "1879-6257",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Oncolytic viruses

T2 - perspectives on clinical development

AU - Burke, James

AU - Nieva, Jorge

AU - Borad, Mitesh J

AU - Breitbach, Caroline J.

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.

AB - Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.

UR - http://www.scopus.com/inward/record.url?scp=84931268628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931268628&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2015.03.020

DO - 10.1016/j.coviro.2015.03.020

M3 - Article

VL - 13

SP - 55

EP - 60

JO - Current Opinion in Virology

JF - Current Opinion in Virology

SN - 1879-6257

M1 - 486

ER -